Nuernisha Alifu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nuernisha Alifu has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Zhong Du
The Second Affiliated Hospital of Xinjiang Medical University The Second School of Clinical Medicine Xinjiang Medical University Urumqi People's Republic of China
22 shared publicationsRong Ma
18 shared publications- Biao Dong
State Key Laboratory on Integrated Optoelectronics, College of Electronic Science and Engineering, Jilin University, Changchun 130012, PR China
17 shared publications Lijun Zhu
The Second Affiliated Hospital of Xinjiang Medical, Xinjiang Medical University Affiliated Second Hospital, Xinjiang Medical university, Urumqi, Xinjiang, 830028, China
17 shared publicationsJiabao Xiong
Xinjiang Medical University
14 shared publicationsTing Yan
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830011, China
12 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Advanced Functional Materials
- p. e78549
Hydrogen Selenide Gas Therapy Integrated With NIR‐II Multimodal Imaging for Precision Theranostics of Cervical Cancer
Cervical cancer treatment is hindered by drug resistance, systemic toxicity, and poor real‐time monitoring of therapy. Herein, we present an intelligent nanotheranostic platform, recombinant human serum albumin (rHSA)‐indocyanine green (ICG)‐Bi 2 (SeO 3 ) 3 (HIB) based on hydrogen selenide (H 2 Se) gas therapy and multimodal imaging. In response to high glutathione (GSH) levels in the tumor microenvironment and under 808 nm laser irradiation, HIB NCs achieve on‐demand H 2 Se release, which sensitizes photothermal/photodynamic therapy and promoted autophagy by regulating heat shock proteins 70 (HSP70) and oxidative stress pathways, as validated by bioinformatics. Distinct from conventional gas agents, HIB NCs enable real‐time, non‐invasive dynamic monitoring of H 2 Se distribution and therapeutic responses using an integrated near‐infrared II (900–1700 nm, NIR‐II) fluorescence/computed tomography (CT)/photoacoustic (PA)/laser speckle contrast imaging (LSCI) multimodal strategy, overcoming the lack of in vivo H 2 Se sensing. In the cervical cancer lymph node metastasis model, HIB NCs could identify diseased lymph nodes more quickly for tracing and exhibit good biocompatibility. This study explored H 2 Se as a potent anti‐metastatic gas messenger and constructed a clinically translatable platform that combines precise gas release, multimodal dynamic monitoring, and synergistic phototherapy.
- 21 September 2026
- Published by Wiley in Advanced Functional Materials
- p. e78549
Open AccessHydrogen Selenide Gas Therapy Integrated With NIR‐II Multimodal Imaging for Precision Theranostics of Cervical Cancer
Cervical cancer treatment is hindered by drug resistance, systemic toxicity, and poor real‐time monitoring of therapy. Herein, we present an intelligent nanotheranostic platform, recombinant human serum albumin (rHSA)‐indocyanine green (ICG)‐Bi 2 (SeO 3 ) 3 (HIB) based on hydrogen selenide (H 2 Se) gas therapy and multimodal imaging. In response to high glutathione (GSH) levels in the tumor microenvironment and under 808 nm laser irradiation, HIB NCs achieve on‐demand H 2 Se release, which sensitizes photothermal/photodynamic therapy and promoted autophagy by regulating heat shock proteins 70 (HSP70) and oxidative stress pathways, as validated by bioinformatics. Distinct from conventional gas agents, HIB NCs enable real‐time, non‐invasive dynamic monitoring of H 2 Se distribution and therapeutic responses using an integrated near‐infrared II (900–1700 nm, NIR‐II) fluorescence/computed tomography (CT)/photoacoustic (PA)/laser speckle contrast imaging (LSCI) multimodal strategy, overcoming the lack of in vivo H 2 Se sensing. In the cervical cancer lymph node metastasis model, HIB NCs could identify diseased lymph nodes more quickly for tracing and exhibit good biocompatibility. This study explored H 2 Se as a potent anti‐metastatic gas messenger and constructed a clinically translatable platform that combines precise gas release, multimodal dynamic monitoring, and synergistic phototherapy.
- Open Access
- 13 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
J-aggregated NIR-II IR-820-based theranostic γ-PGA-nanoplatform for NO-enhanced photothermal therapy of cervical cancer
- 13 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
Open AccessJ-aggregated NIR-II IR-820-based theranostic γ-PGA-nanoplatform for NO-enhanced photothermal therapy of cervical cancer
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (31) , 9764-9779
Tumor microenvironment-activated HA@GOx/IR-820@MnO 2 nanosheets for dual-modal imaging guided phototherapy of cervical cancer
Tumor microenvironment-responsive nanosheets with self-supplying oxygen and dual-modal imaging capabilities enable synergistic phototherapy and enhanced antitumor efficacy in a cervical cancer model.
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (31) , 9764-9779
Tumor microenvironment-activated HA@GOx/IR-820@MnO 2 nanosheets for dual-modal imaging guided phototherapy of cervical cancer
Tumor microenvironment-responsive nanosheets with self-supplying oxygen and dual-modal imaging capabilities enable synergistic phototherapy and enhanced antitumor efficacy in a cervical cancer model.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (31) , 14854-14871
Hollow Manganese-Based Nanoplatform for NIR-II/MRI Imaging-Guided Chemo/Chemodynamic/Photo-Therapy of Cancer
Hollow manganese-dioxide-based nanoplatforms, which combine hollow structures with the intrinsic theranostic properties of Mn2+, have shown great potential for precise tumor diagnosis and treatment. However, single imaging or therapeutic modalities are still insufficient for high requirements of precise cancer theranostics. Herein, a hollow manganese-based theranostic nanoplatform, MnO2–IR-820-Q/DOX@TMTP1 nanocomposite (Mn-NCs), was designed and synthesized. With the assistance of the Mn-NCs, near-infrared-II (NIR-II, 900–1700 nm) fluorescence imaging with high spatial resolution and low autofluorescence was combined with magnetic resonance imaging (MRI) for highly efficient and precise multimodal imaging of cervical tumors. The organic cyanine dye IR-820 and PbS@CdS quantum dots (QDs) were integrated to form a hybrid nanocomposite (IR-820-Q) with strong NIR-II fluorescence emission, which was subsequently assembled onto a MnO2 nanocarrier to enable MRI and protect IR-820-Q from degradation. The hollow MnO2 nanoshells served as a nanoscale structural framework for IR-820-Q/DOX loading, tumor microenvironment-responsive degradation, and Mn2+-mediated imaging/therapeutic functions. The cervical tumor-targeting peptide TMTP1 was introduced to improve the tumor-targeting potential of the nanocomposite, enabling NIR-II fluorescence visualization of primary tumors and lymph node metastatic lesions. Therefore, Mn-NCs are well suited for tumor-targeted imaging-guided intervention of cervical cancer and lymphatic metastasis. By constructing the theranostic nanoplatform, the photothermal therapy (PTT) as well as photodynamic therapy (PDT) effect from the IR-820 was enhanced, and with the hydroxyl radicals (via Fenton-like reaction) of Mn2+ in the tumor microenvironment, effective chemodynamic therapy (CDT) was also achieved. The loading of doxorubicin (DOX) further endowed the nanoplatform with a chemotherapeutic capability. Thus, the developed theranostic nanoplatform showed strong NIR-II fluorescence/MRI-guided synergistic PTT/PDT/CDT and chemotherapy, which significantly improved the therapeutic outcomes. This study demonstrates a promising strategy for precise cervical cancer diagnosis and treatment, highlighting the potential of organic–inorganic hybrid nanomaterials for clinical translation.
- 29 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (31) , 14854-14871
Hollow Manganese-Based Nanoplatform for NIR-II/MRI Imaging-Guided Chemo/Chemodynamic/Photo-Therapy of Cancer
Hollow manganese-dioxide-based nanoplatforms, which combine hollow structures with the intrinsic theranostic properties of Mn2+, have shown great potential for precise tumor diagnosis and treatment. However, single imaging or therapeutic modalities are still insufficient for high requirements of precise cancer theranostics. Herein, a hollow manganese-based theranostic nanoplatform, MnO2–IR-820-Q/DOX@TMTP1 nanocomposite (Mn-NCs), was designed and synthesized. With the assistance of the Mn-NCs, near-infrared-II (NIR-II, 900–1700 nm) fluorescence imaging with high spatial resolution and low autofluorescence was combined with magnetic resonance imaging (MRI) for highly efficient and precise multimodal imaging of cervical tumors. The organic cyanine dye IR-820 and PbS@CdS quantum dots (QDs) were integrated to form a hybrid nanocomposite (IR-820-Q) with strong NIR-II fluorescence emission, which was subsequently assembled onto a MnO2 nanocarrier to enable MRI and protect IR-820-Q from degradation. The hollow MnO2 nanoshells served as a nanoscale structural framework for IR-820-Q/DOX loading, tumor microenvironment-responsive degradation, and Mn2+-mediated imaging/therapeutic functions. The cervical tumor-targeting peptide TMTP1 was introduced to improve the tumor-targeting potential of the nanocomposite, enabling NIR-II fluorescence visualization of primary tumors and lymph node metastatic lesions. Therefore, Mn-NCs are well suited for tumor-targeted imaging-guided intervention of cervical cancer and lymphatic metastasis. By constructing the theranostic nanoplatform, the photothermal therapy (PTT) as well as photodynamic therapy (PDT) effect from the IR-820 was enhanced, and with the hydroxyl radicals (via Fenton-like reaction) of Mn2+ in the tumor microenvironment, effective chemodynamic therapy (CDT) was also achieved. The loading of doxorubicin (DOX) further endowed the nanoplatform with a chemotherapeutic capability. Thus, the developed theranostic nanoplatform showed strong NIR-II fluorescence/MRI-guided synergistic PTT/PDT/CDT and chemotherapy, which significantly improved the therapeutic outcomes. This study demonstrates a promising strategy for precise cervical cancer diagnosis and treatment, highlighting the potential of organic–inorganic hybrid nanomaterials for clinical translation.
- 25 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (26) , 36534-36546
Supramolecular Reactivation of Quenched Silicon Naphthalocyanine for NIR-II Fluorescence-Guided Type I/II Photodynamic Monotherapy
Silicon 2,3-naphthalocyanine bis(trihexylsilyloxide) (SiNc) possesses intense near-infrared absorption, promising NIR-II emission, and a high reactive oxygen species quantum yield in its monomeric state. However, its potential as a NIR-II fluorescent photosensitizer has been long hindered by aggregation-caused quenching in aqueous environments. Herein, we report a supramolecular engineering strategy to overcome this limitation by precisely tuning the molecular packing of SiNc within a biocompatible DSPE-PEG2000 matrix. Through systematic optimization of the dye-to-matrix ratio, initial dye concentration, and solvent composition, we obtain optimized nanoparticles (SiNc NPs) that effectively disrupt tight π-π stacking. Compared to severely quenched control nanoparticles (Ctrl-NPs), SiNc NPs exhibit a 3-fold enhancement in fluorescence quantum yield (4.2% vs 1.4%), alongside 17.7-fold and 8.7-fold increases in 1O2 (ΦΔ = 10.6% vs 0.6%) and O2•- generation, respectively. Consequently, SiNc NPs deliver potent NIR-II fluorescence-guided photodynamic efficacy in vivo. Following a single low-dose intravenous injection and one session of 781 nm laser irradiation, SiNc NPs achieve near-complete 4T1 tumor eradication, showing improved efficacy compared to both a clinical photosensitizer (Ce6) and Ctrl-NPs under the tested conditions. This work establishes a programmable supramolecular paradigm for reactivating highly quenched, aggregation-prone chromophores, offering a practical alternative to complex de novo synthesis in the pursuit of high-performance NIR-II fluorescent photosensitizers capable of effective photodynamic monotherapy.
- 25 June 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 18 (26) , 36534-36546
Supramolecular Reactivation of Quenched Silicon Naphthalocyanine for NIR-II Fluorescence-Guided Type I/II Photodynamic Monotherapy
Silicon 2,3-naphthalocyanine bis(trihexylsilyloxide) (SiNc) possesses intense near-infrared absorption, promising NIR-II emission, and a high reactive oxygen species quantum yield in its monomeric state. However, its potential as a NIR-II fluorescent photosensitizer has been long hindered by aggregation-caused quenching in aqueous environments. Herein, we report a supramolecular engineering strategy to overcome this limitation by precisely tuning the molecular packing of SiNc within a biocompatible DSPE-PEG2000 matrix. Through systematic optimization of the dye-to-matrix ratio, initial dye concentration, and solvent composition, we obtain optimized nanoparticles (SiNc NPs) that effectively disrupt tight π-π stacking. Compared to severely quenched control nanoparticles (Ctrl-NPs), SiNc NPs exhibit a 3-fold enhancement in fluorescence quantum yield (4.2% vs 1.4%), alongside 17.7-fold and 8.7-fold increases in 1O2 (ΦΔ = 10.6% vs 0.6%) and O2•- generation, respectively. Consequently, SiNc NPs deliver potent NIR-II fluorescence-guided photodynamic efficacy in vivo. Following a single low-dose intravenous injection and one session of 781 nm laser irradiation, SiNc NPs achieve near-complete 4T1 tumor eradication, showing improved efficacy compared to both a clinical photosensitizer (Ce6) and Ctrl-NPs under the tested conditions. This work establishes a programmable supramolecular paradigm for reactivating highly quenched, aggregation-prone chromophores, offering a practical alternative to complex de novo synthesis in the pursuit of high-performance NIR-II fluorescent photosensitizers capable of effective photodynamic monotherapy.
- Open Access
- 17 June 2026
- Published by Elsevier in SSRN Electronic Journal
cRGD-Modified Liposomes with Enhanced Blood-Tumor Barrier Penetration Enabling NO-Mediated Modulation of Chemoresistance in Orthotopic Glioblastoma
Glioblastoma (GBM) remains one of the most lethal brain malignancies, largely due to the blood-brain barrier (BBB) and the pathologically heterogeneous blood-tumor barrier (BTB), which severely restrict drug delivery. To achieve targeted BBB/BTB traversal, we developed cRGD-modified ICG/TMZ@Lips nanoparticles (ITC NPs). The nanoplatform actively targets αvβ3 integrin overexpressed on tumor endothelial cells and GBM cells, thereby promoting receptor-mediated transport and tumor penetration. Under near-infrared (NIR) irradiation, ITC NPs trigger temozolomide (TMZ) release and photo-responsive NO-associated effects. These effects are accompanied by heat shock protein 70 (HSP70) downregulation and modulation of resistance-related pathways, which may contribute to enhanced chemosensitivity. Furthermore, we integrated near-infrared II (NIR-II) fluorescence imaging with laser speckle contrast imaging (LSCI) for real-time GBM diagnosis and perfusion monitoring. To the best of our knowledge, among existing BBB/BTB traversal strategies, this is the first study to apply cRGD peptide for specific and efficient BBB/BTB penetration in GBM therapy. This strategy directly addresses the fundamental limitations imposed by the heterogeneous and efflux‐active BTB, offering a precise nanomedicine approach for improved therapeutic outcomes.
- 17 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccesscRGD-Modified Liposomes with Enhanced Blood-Tumor Barrier Penetration Enabling NO-Mediated Modulation of Chemoresistance in Orthotopic Glioblastoma
Glioblastoma (GBM) remains one of the most lethal brain malignancies, largely due to the blood-brain barrier (BBB) and the pathologically heterogeneous blood-tumor barrier (BTB), which severely restrict drug delivery. To achieve targeted BBB/BTB traversal, we developed cRGD-modified ICG/TMZ@Lips nanoparticles (ITC NPs). The nanoplatform actively targets αvβ3 integrin overexpressed on tumor endothelial cells and GBM cells, thereby promoting receptor-mediated transport and tumor penetration. Under near-infrared (NIR) irradiation, ITC NPs trigger temozolomide (TMZ) release and photo-responsive NO-associated effects. These effects are accompanied by heat shock protein 70 (HSP70) downregulation and modulation of resistance-related pathways, which may contribute to enhanced chemosensitivity. Furthermore, we integrated near-infrared II (NIR-II) fluorescence imaging with laser speckle contrast imaging (LSCI) for real-time GBM diagnosis and perfusion monitoring. To the best of our knowledge, among existing BBB/BTB traversal strategies, this is the first study to apply cRGD peptide for specific and efficient BBB/BTB penetration in GBM therapy. This strategy directly addresses the fundamental limitations imposed by the heterogeneous and efflux‐active BTB, offering a precise nanomedicine approach for improved therapeutic outcomes.
- Open Access
- 14 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (28) , 25705-25716
Designable NIR-II light triggered biocompatible Au NRs for highly efficient photothermal therapy of cervical cancer
Gold nanorods (Au NRs) hold great potential for photothermal therapy (PTT) of cervical cancer, but their clinical application is hindered by suboptimal absorbance in the second near-infrared (900–1700 nm, NIR-II) spectral window, synthetic heterogeneity, and cytotoxic surfactant residues. To overcome these limitations, we combined computational design with experimental synthesis and developed novel type of NIR-II-optimized Au NRs. Finite-difference time-domain simulations predicted that Au NRs exhibited 88 nm of length and 13 nm of diameter with a strong localized surface plasmon resonance (LSPR) peak at 1058 nm, enabling deep tissue penetration in the NIR-II spectral region. Experimentally, we synthesized highly uniform Au NRs@PEG nanoparticles (NPs) via a seed-growth method, achieving a 1026 nm absorption peak while replacing toxic cetyltrimethylammonium bromide (CTAB) with biocompatible polyethylene glycol (SH-PEG-5000). The Au NRs@PEG demonstrated exceptional photothermal conversion efficiency of 60.89%, excellent tumor accumulation, and minimal systemic toxicity. In vivo studies confirm effective tumor suppression of 93.5% under NIR-II light excitation, with the stability for repeated treatment cycles. In this work, we introduce a versatile paradigm for designing high-performance, clinically viable photothermal agents by means of rational optical engineering and surface modification.
- 14 May 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (28) , 25705-25716
Open AccessDesignable NIR-II light triggered biocompatible Au NRs for highly efficient photothermal therapy of cervical cancer
Gold nanorods (Au NRs) hold great potential for photothermal therapy (PTT) of cervical cancer, but their clinical application is hindered by suboptimal absorbance in the second near-infrared (900–1700 nm, NIR-II) spectral window, synthetic heterogeneity, and cytotoxic surfactant residues. To overcome these limitations, we combined computational design with experimental synthesis and developed novel type of NIR-II-optimized Au NRs. Finite-difference time-domain simulations predicted that Au NRs exhibited 88 nm of length and 13 nm of diameter with a strong localized surface plasmon resonance (LSPR) peak at 1058 nm, enabling deep tissue penetration in the NIR-II spectral region. Experimentally, we synthesized highly uniform Au NRs@PEG nanoparticles (NPs) via a seed-growth method, achieving a 1026 nm absorption peak while replacing toxic cetyltrimethylammonium bromide (CTAB) with biocompatible polyethylene glycol (SH-PEG-5000). The Au NRs@PEG demonstrated exceptional photothermal conversion efficiency of 60.89%, excellent tumor accumulation, and minimal systemic toxicity. In vivo studies confirm effective tumor suppression of 93.5% under NIR-II light excitation, with the stability for repeated treatment cycles. In this work, we introduce a versatile paradigm for designing high-performance, clinically viable photothermal agents by means of rational optical engineering and surface modification.
- Open Access
- 28 April 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (3)
Tumor cell membrane modified clinical lCG nanoprobes for NIR fluorescence imaging of targeted triple negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtype with high metastatic and recurrence rates. However there is still a lack of effective targeting nanoprobes (NPs) which is leading to suboptimal targeted therapy. Cell membrane-encapsulation methods are one of an ideal targeting strategy, which could enhance the biocompatibility through endogenous membrane components while enabling functional integration of targeting and imaging capabilities. In this study, fluorescent dye-clinical indocyanine green (ICG) was successfully encapsulated by TNBC cell membranes via dual biolayer method to form M-ICG NPs. The M-ICG NPs exhibited well optical/photothermal property and stability while maintaining the advantage of TNBC targeting ability. Thus, the M-ICG NPs achieved well cancer-specific labeling and targeted near infrared (NIR) fluorescence imaging, offering a foundational framework for developing multifunctional nanoplatforms with tumor-specific targeting, enhanced biocompatibility, and structural stability for in vivo theranostic applications.
- 28 April 2026
- Published by IOP Publishing in Biomedical Materials
- Vol. 21 (3)
Open AccessTumor cell membrane modified clinical lCG nanoprobes for NIR fluorescence imaging of targeted triple negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtype with high metastatic and recurrence rates. However there is still a lack of effective targeting nanoprobes (NPs) which is leading to suboptimal targeted therapy. Cell membrane-encapsulation methods are one of an ideal targeting strategy, which could enhance the biocompatibility through endogenous membrane components while enabling functional integration of targeting and imaging capabilities. In this study, fluorescent dye-clinical indocyanine green (ICG) was successfully encapsulated by TNBC cell membranes via dual biolayer method to form M-ICG NPs. The M-ICG NPs exhibited well optical/photothermal property and stability while maintaining the advantage of TNBC targeting ability. Thus, the M-ICG NPs achieved well cancer-specific labeling and targeted near infrared (NIR) fluorescence imaging, offering a foundational framework for developing multifunctional nanoplatforms with tumor-specific targeting, enhanced biocompatibility, and structural stability for in vivo theranostic applications.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-19
Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer
Cervical cancer (CC) is still the fourth most common cause of cancer deaths in women. However, current biomedical imaging techniques exhibit inherent limitations in the diagnosis and treatment of CC. This study aims to develop a biomimetic nanoplatform based on tumor cell membranes, loaded with a palladium (Pd)-based computed tomography (CT) contrast agent and the near-infrared (NIR) fluorescent probe indocyanine green (ICG). This multifunctional nanoplatform is designed to integrate multimodal imaging with photothermal therapy (PTT), thereby improving the diagnostic accuracy and therapeutic efficacy against CC. In this study, biomimetic nanoparticles (NPs), designated as M@Pd-ICG NPs, were synthesized by encapsulating Pd and ICG within HeLa cell membranes derived from cell-derived xenograft (CDX) models. Subsequently, the toxicity, biocompatibility, and tumor suppression capability of the M@Pd-ICG NPs were evaluated in vitro. In vivo, the multimodal imaging performance of the M@Pd-ICG NPs and their photothermal therapeutic efficacy under 808-nm laser irradiation were investigated in mouse model bearing subcutaneous cervical tumor. The M@Pd-ICG NPs were successfully prepared and exhibited favorable stability, excellent photothermal conversion efficiency (34.04%), and good biocompatibility, enabling homologous targeting and prolonged circulation time. The M@Pd-ICG NPs integrated the complementary advantages of NIR-II fluorescence imaging (900–1700 nm, NIR-II FI), photothermal imaging (PTI), and CT imaging. Both in vitro and in vivo studies demonstrated that, under 808-nm laser irradiation, M@Pd-ICG NPs induced significant photothermal effects and tumor ablation. M@Pd-ICG NPs successfully integrate multimodal imaging and PTT, owing to their excellent targeting capability and good biocompatibility, demonstrating potential for further biomedical applications.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-19
Open AccessTargetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer
Cervical cancer (CC) is still the fourth most common cause of cancer deaths in women. However, current biomedical imaging techniques exhibit inherent limitations in the diagnosis and treatment of CC. This study aims to develop a biomimetic nanoplatform based on tumor cell membranes, loaded with a palladium (Pd)-based computed tomography (CT) contrast agent and the near-infrared (NIR) fluorescent probe indocyanine green (ICG). This multifunctional nanoplatform is designed to integrate multimodal imaging with photothermal therapy (PTT), thereby improving the diagnostic accuracy and therapeutic efficacy against CC. In this study, biomimetic nanoparticles (NPs), designated as M@Pd-ICG NPs, were synthesized by encapsulating Pd and ICG within HeLa cell membranes derived from cell-derived xenograft (CDX) models. Subsequently, the toxicity, biocompatibility, and tumor suppression capability of the M@Pd-ICG NPs were evaluated in vitro. In vivo, the multimodal imaging performance of the M@Pd-ICG NPs and their photothermal therapeutic efficacy under 808-nm laser irradiation were investigated in mouse model bearing subcutaneous cervical tumor. The M@Pd-ICG NPs were successfully prepared and exhibited favorable stability, excellent photothermal conversion efficiency (34.04%), and good biocompatibility, enabling homologous targeting and prolonged circulation time. The M@Pd-ICG NPs integrated the complementary advantages of NIR-II fluorescence imaging (900–1700 nm, NIR-II FI), photothermal imaging (PTI), and CT imaging. Both in vitro and in vivo studies demonstrated that, under 808-nm laser irradiation, M@Pd-ICG NPs induced significant photothermal effects and tumor ablation. M@Pd-ICG NPs successfully integrate multimodal imaging and PTT, owing to their excellent targeting capability and good biocompatibility, demonstrating potential for further biomedical applications.
- 25 February 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (11) , 3427-3441
NIR-activated dual-mode oxygen-generating and -delivering nanoplatform for enhanced photodynamic therapy of cervical cancer
NIR-activated IFHFC nanoparticles enable NIR-I/NIR-II imaging and dual oxygenation (CAT-catalyzed O 2 generation and PFH O 2 release), relieving hypoxia and boosting ROS for enhanced PDT.
- 25 February 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (11) , 3427-3441
NIR-activated dual-mode oxygen-generating and -delivering nanoplatform for enhanced photodynamic therapy of cervical cancer
NIR-activated IFHFC nanoparticles enable NIR-I/NIR-II imaging and dual oxygenation (CAT-catalyzed O 2 generation and PFH O 2 release), relieving hypoxia and boosting ROS for enhanced PDT.